 SAN RAFAEL, Calif., July 15, 2021 PRNewswire -- BioMarin Pharmaceutical Inc. NASDAQ: BMRN announced today that the European Medicines Agency EMA validated the Companys Marketing Authorization Application MAA for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. 